{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T18:20:08Z","timestamp":1760984408431,"version":"build-2065373602"},"reference-count":20,"publisher":"Wiley","issue":"22","license":[{"start":{"date-parts":[[2012,4,27]],"date-time":"2012-04-27T00:00:00Z","timestamp":1335484800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2012,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>The authors performed a phase 2 study of bevacizumab plus pemetrexed and carboplatin followed by maintenance bevacizumab in patients with advanced, nonsquamous nonsmall cell lung cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>Previously untreated patients with advanced, nonsquamous nonsmall cell lung cancer and an Eastern Cooperative Oncology Group performance status of 0 or 1 received bevacizumab 15 mg\/kg, pemetrexed 500 mg\/m<jats:sup>2<\/jats:sup> and carboplatin at an area under the concentration\u2010time curve of 6 intravenously on day 1 every 21 days. Responding or stable patients who completed 6 cycles then received bevacizumab maintenance every 21 days until disease progression.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>In total, 43 patients (40 who were evaluable for response) were entered on the study. Treatment\u2010related grade 3\/4 toxicities were low and included febrile neutropenia (2%), neutropenia (28%), anemia (18%), thrombocytopenia (11%), hypertension (7%), epistaxis (5%), venous thrombosis (8%), dyspnea (7%), rectovaginal fistula (2.3%), infusion reaction (2%), and cerebrovascular event (2%). One patient died from complications of venous thromboembolism and cerebrovascular accident after Cycle 2. Minimal clinically significant toxicity occurred during maintenance bevacizumab. Two complete responses (5%) were observed, and 17 patients (42%) had a partial response. Fifteen patients (38%) displayed disease stability. The overall disease control rate was 85%. At a median follow\u2010up of 15.8 months, the median progression\u2010free survival was 7.1 months (95% confidence interval, 5.9\u20108.3 months), and the median overall survival was 17.1 months (95% confidence interval, 8.8\u201025.5 months).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Combined bevacizumab, pemetrexed, and carboplatin followed by maintenance bevacizumab was well tolerated and displayed remarkable activity in patients with previously untreated, advanced, nonsquamous nonsmall cell lung cancer. Cancer 2012. \u00a9 2012 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.27576","type":"journal-article","created":{"date-parts":[[2012,4,27]],"date-time":"2012-04-27T15:59:18Z","timestamp":1335542358000},"page":"5580-5587","source":"Crossref","is-referenced-by-count":17,"title":["Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer"],"prefix":"10.1002","volume":"118","author":[{"given":"James P.","family":"Stevenson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey J.","family":"Langer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Somer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracey L.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kumar","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Krieger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona","family":"Jacobs\u2010Small","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolas","family":"Dyanick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry","family":"Milcarek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Coakley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Eaby\u2010Sandy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Hageboutros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,4,27]]},"reference":[{"volume-title":"SEER Cancer Statistics Review 1975\u20102008","author":"Howlander M","key":"e_1_2_6_2_2"},{"key":"e_1_2_6_3_2","first-page":"2893","article-title":"Estimating of worldwide burden of cancer in 2008: Globocan 2008","volume":"127","author":"Parkin DM","year":"2008","journal-title":"Int J Cancer."},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20121"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.311.7010.899"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011954"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.03.195"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.163"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.0375"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.022"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq020"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61497-5"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8181"},{"key":"e_1_2_6_15_2","unstructured":"Genentech Inc.Avastin product information. Available at:http:\/\/www.gene.com\/gene\/products\/information\/oncology\/avastin\/. [Accessed April 5 2012.]"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182307efe"},{"key":"e_1_2_6_17_2","unstructured":"Eli Lilly and Company. A study of pemetrexed carboplatin and bevacizumab in patients with nonsquamous non\u2010small cell lung cancer. National Clinical Trial NCT00762034. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00762034. [Accessed April 5 2012.]"},{"key":"e_1_2_6_18_2","unstructured":"Hoffmann\u2010La Roche. AVAPERL1 study: a study of Avastin (bevacizumab) with or without pemetrexed as maintenance therapy after Avastin in first line in patients with non\u2010squamous non\u2010small cell lung cancer. National Clinical Trial NCT00961415. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00961415. [Accessed April 5 2012.]"},{"key":"e_1_2_6_19_2","doi-asserted-by":"crossref","unstructured":"BarlesiF de CastroJ DvornichenkoV et al.AVAPERL (MO22089): final efficacy outcomes for patients with advanced non\u2010squamous non\u2010small cell lung cancer (nsNSCLC) randomised to continuation maintenance (mtc) with bevacizumab (bev) or bev+pemetrexed (pem) after first\u2010line (1L) bev\u2010cisplatin (cis)\u2010pem treatment (Tx). Paper presented at: 2011 European Multidisciplinary Cancer Congress; September 23\u201327 2011; Stockholm Sweden. Abstract 34LBA.","DOI":"10.1016\/S0959-8049(11)70133-2"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djk196"},{"key":"e_1_2_6_21_2","unstructured":"Eastern Cooperative Oncology Group National Cancer Institute. Bevacizumab or pemetrexed disodium alone or in combination after induction therapy in treating patients with advanced non\u2010squamous non\u2010small cell lung cancer. National Clinical Trial NCT01107626. Available at:http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01107626. [Accessed April 5 2012.]"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.27576","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.27576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:25:34Z","timestamp":1760268334000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.27576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,27]]},"references-count":20,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2012,11,15]]}},"alternative-id":["10.1002\/cncr.27576"],"URL":"https:\/\/doi.org\/10.1002\/cncr.27576","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"type":"print","value":"0008-543X"},{"type":"electronic","value":"1097-0142"}],"subject":[],"published":{"date-parts":[[2012,4,27]]}}}